Nurix Therapeutics Shares Fall After Sanofi Discontinues STAT6 Drug Program

02:50 PM EST, 11/04/2026 (MT Newswires) -- Nurix Therapeutics (NRIX) shares fell 36.9% in Wednesday trading after Sanofi (SNY) notified the company of its decision to discontinue the phase 1 first-in-human trial of oral STAT6 degrader SAR448272 and terminate the program. Nurix said late Tuesday it does not expect to receive any future development, regulatory or commercial milestone payments or royalties related to SAR448272. The company remains eligible to receive milestone payments and royalties from other previously licensed programs under its collaboration with Sanofi, which the drugmaker may choose to develop further into clinical candidates, according to a statement. Nurix added that its cash, cash equivalents and marketable securities totaled $1.1 billion as of Aug. 31, providing sufficient funding to support operations into the second half of 2029. Price: 16.31, Change: -9.52, Percent Change: -36.85